Trial Profile
A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Ravidasvir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms Pyramid 1
- Sponsors Pharco Corporation
- 18 Sep 2017 Results published in the Journal of Hepatology
- 17 Apr 2016 Results presented at The International Liver Congress 2016
- 06 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.